Secura Bio Withdraws U.S. Oncology Indications for Copiktra, Farydak
Both Copiktra and Farydak had received accelerated approvals, and the FDA had required confirmatory trials. Secura Bio has determined such trials are not feasible.
Secura Bio has voluntarily withdrawn oncology indications for two of its therapies. The company has withdrawn the U.S. indication of Copiktra (duvelisib) for the treatment of patients with relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.
The relapsed or refractory FL indication received accelerated approval in September 2018 with the requirement that an additional confirmatory trial be conducted in order for the product to be granted full approval.
Company officials stressed this is a business decision and is not related to any changes in either the efficacy or safety associated with the therapy but with the logistics, cost and timing of the postmarketing requirements.
This decision impacts only the relapsed or refractory follicular lymphoma indication and does not affect other approved indications in the United States and other countries, including the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after at least two prior therapies.
Copiktra is an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first FDA-approved dual inhibitor of PI3K-delta and PI3K-gamma, two enzymes known to help support the growth and survival of malignant cells.
In addition, Secura Bio has withdrawn the NDA approval of Farydak (panobinostat) oral capsules, which received accelerated approval in February 2015 for use in combination with bortezomib and dexamethasone to treat patients with multiple myeloma who have received at least two prior regimens. Secura Bio acquired the therapy in March 2019.
The accelerated approval was based on progression-free survival and consistent with FDA regulations, required further adequate and well-controlled clinical studies to verify and describe the product's clinical benefit. In its withdrawal submission, Secura Bio noted that, as previously discussed with FDA, it was not feasible for the company to complete the required post-approval clinical studies as designed as part of the accelerated approval process.
Secura Bio and its partners will continue to market Farydak in other markets where it has been approved.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Using the 'Pathway' Approach to Shorten the Time Between Cancer Diagnosis and Treatment
August 1st 2025In this episode of Tuning In to the C-Suite, Briana Contreras, editor with Managed Healthcare Executive spoke with Dr. Yuri Fesko, oncologist and vice president of Medical Affairs at Quest Diagnostics. In the conversation, Dr. Fesko addressed the ongoing issue of long gaps of times between receiving a diagnosis for a type of cancer and finally getting the treatment for it. Dr. Fesko shared the benefits a number of sectors receive when treating patients sooner and the steps to get there.
Listen
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
August 1st 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
August 1st 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More
